Cutaneous squamous cell carcinoma affecting the head and neck often requires extensive surgery and complex reconstructive tissue transfers. A review published in Cureus examines surgical de-escalation strategies following neoadjuvant immunotherapy, evaluating whether pathological responses to checkpoint inhibitors safely allow patients to avoid disfiguring operations.
In Plain English: The Clinical Takeaway
- Neoadjuvant Immunotherapy: Administering programmed death-1 (PD-1) blocking drugs before surgery shrinks tumors while they remain intact for immune system recognition.
- Surgical De-escalation: Treatment-driven shrinkage in the scope of a planned surgical excision or reconstructive operation, which may involve safeguarding a vulnerable anatomical part.
- Pathological Complete Response (pCR): The complete absence of viable tumor cells in the surgical specimen after resection, serving as a primary marker for treatment efficacy.
Assessing Surgical Extent After Checkpoint Inhibition
Surgery combined with histological margin assessment remains the foundation of treatment for resectable cutaneous squamous cell carcinoma. When tumors develop in sensitive areas such as the head and neck, successful excision might necessitate the extraction of an eyelid, lip, facial nerve, orbit, or neighboring bone, followed by intricate reconstruction. The 2026 European consensus guideline emphasises clear margins and individualised management of advanced disease.
Key takeaways from the Head and Neck Tumor Board discussion at #ANCO #MMC26 included emerging roles for perioperative immunotherapy such as pembrolizumab in resectable head and neck cancer, evolving use of neoadjuvant and adjuvant immunotherapy for high risk cutaneous squamous… pic.twitter.com/bzU0nXuvIT
To mitigate the morbidity of such extensive resections, clinical investigators have evaluated neoadjuvant PD-1 inhibitors such as cemiplimab and pembrolizumab. By administering these systemic therapies prior to surgery, clinicians aim to reduce the tumor burden. However, establishing a pathological complete response requires examining the resected tissue, which introduces clinical uncertainty regarding whether preoperative imaging or clinical regression accurately reflects the true absence of disease in deep tissues or regional lymph node basins.
The Cureus review synthesizes prospective trials and retrospective cohorts investigating response-adapted surgery. For instance, the pilot study led by Ferrarotto and its subsequent follow-up evaluated twenty patients treated with cemiplimab, observing a pathological complete response in eleven participants. While seventeen of twenty patients remained disease-free at a median follow-up of 42.3 months, all three recurrences occurred in nonresponders. Crucially, that trial maintained standard surgical resection boundaries regardless of tumor shrinkage, establishing prognostic correlation rather than testing reduced surgical margins.
Evaluating Prospective Trials and Organ Preservation Protocols
Data from prospective single-arm phase II trials demonstrate varying approaches to surgical modification after immunotherapy. The multicentre trial by Gross and colleagues enrolled seventy-nine patients receiving up to four doses of cemiplimab, with seventy participants eventually proceeding to surgery. Investigators documented a pathological complete response rate of 51% alongside an event-free survival rate of 89% at twelve months, with illustrative anatomical preservation reported.
Direct prospective evidence regarding surgical modification emerged from the DISCERN trial, which evaluated eleven patients. Researchers recorded the intended surgical plan prior to immunotherapy and compared it directly with the operation ultimately performed. All eight patients who achieved a pathological complete response underwent less extensive surgery than initially planned; conversely, three patients with disease progression required more extensive surgical intervention.
Other trials explored the complete omission of local therapy. The MATISSE randomized trial evaluated nivolumab with or without ipilimumab in fifty patients, forty of whom underwent surgery. Ten patients declined local therapy, with nine achieving complete clinical remission and remaining cancer-free at a median subgroup follow-up of 34 months. Meanwhile, the De-Squamate trial tested a protocol where patients achieving a complete metabolic response and negative mapping biopsies avoided surgery and radiotherapy entirely, supported by maintenance treatment.
| Clinical Trial | Sample Size (N) | Key Intervention | Primary Reported Outcome |
|---|---|---|---|
| Ferrarotto et al. | 20 | Cemiplimab (2 doses) | pCR in 11/20; 17/20 disease-free at 42.3 months. |
| Gross et al. | 79 | Cemiplimab (up to 4 doses) | pCR 51%; 12-month event-free survival 89%. |
| DISCERN | 11 | Cemiplimab pre-resection | All 8 pCR patients underwent less extensive surgery. |
| MATISSE | 50 | Nivolumab ± ipilimumab | 9 of 10 patients declining local therapy remained cancer-free. |
| De-Squamate | 27 | Pembrolizumab + maintenance | 13/27 avoided surgery/radiotherapy via metabolic response. |
Retrospective Evidence and Surgical Modifiability
Retrospective cohorts provide additional context regarding real-world surgical adaptation. A two-centre cohort reported by Kim and colleagues highlighted the distinction between neoadjuvant intent and completed resection, noting that several patients declined planned operations after experiencing tumor stability or clinical response. This dynamic underscores the challenge of evaluating pathological outcomes exclusively in patients who proceed to surgery.
Conversely, retrospective surgical series like the cohort analyzed by Yaniv examined direct operative modifications. Among forty-one patients, seventeen underwent response-adapted resections while twenty-four received standard operations. Investigators reported successful organ preservation in four patients and the avoidance of intended free flaps in another four, with clear margins 16/17 versus 22/24 and estimated two-year locoregional recurrence-free survival of 95% versus 90%. However, nonrandom patient selection and small sample sizes prevent definitive assertions of noninferiority.
Unresolved Questions in Response-Adapted Oncological Surgery
While current clinical data demonstrate that neoadjuvant PD-1 blockade induces substantial pathological responses and enables anatomical structure preservation in select cohorts, significant evidentiary gaps remain. The safety of omitting surgery entirely or substantially reducing resection margins lacks long-term randomized validation. Establishing standardized criteria for imaging-pathology discordance and defining the precise role of circulating tumor DNA and functional imaging will be essential to determine which patients can safely forgo standard surgical boundaries without compromising long-term disease control.
References
- Cureus. Surgical De-escalation After Neoadjuvant Immunotherapy for Cutaneous Squamous Cell Carcinoma: Oncological Safety and Reconstructive Consequences.
- PubMed/MEDLINE. Clinical trials database search on neoadjuvant PD-1 blockade in cutaneous squamous cell carcinoma.
- European consensus guidelines for the management of advanced cutaneous squamous cell carcinoma.
